COMPLETED RESEARCH: CLINICAL/TRANSLATIONAL RESEARCH
Abstract #CT11

Safety and Antitumor Activity of Dostarlimab in Patients with Advanced or Recurrent DNA Mismatch Repair-Deficient or -Proficient Endometrial Cancer: Results from the GARNET Study

JHOP - March 2021 Vol 11 Special Feature - HOPA Abstracts, Biomarkers, Clinical Trials, Gynecologic Cancers

Presenter: Bhavana Pothuri, Department of Obstetrics and Gynecology, New York University

Co-Authors: Lucy Gilbert, MD, McGill University Health Centre-RI; Anna V. Tinker, MD, BC Cancer; Renaud Sabatier, MD, Department of Medical Oncology, Institut Paoli Calmettes, Aix-Marseille University; Valentina Boni, MD, Centro Integral Oncológico Clara Campal, Hospital Universitario HM Sanchinarro; David M. O’Malley, MD, The Ohio State University–James CCC; Sharad Ghamande, MD, Georgia Cancer Center, Augusta University; Linda Duska, MD, Emily Couric Clinical Cancer Center, University of Virginia; Prafull Ghatage, MD, Department of Gynecological Oncology, University of Calgary; Wei Guo, GlaxoSmithKline; Ellie Im, GlaxoSmithKline; Ana Oaknin, MD, PhD, Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology

Background: Dostarlimab (TSR-042) is a humanized programmed death (PD)-1 receptor monoclonal antibody that blocks interaction with the PD-1 ligands. GARNET (NCT02715284) is a phase 1 study assessing antitumor activity and safety of dostarlimab monotherapy in patients with solid tumors.1

Objective: To explore the impact of mismatch repair status at the response to dostarlimab therapy in patients with recurrent or advanced endometrial cancer that progressed during or after a platinum-based chemotherapy regimen.

Methods: This multicenter, open-label, single-arm study included dose-escalation and expansion parts. We report on 2 independent expansion cohorts of patients with recurrent or advanced endometrial cancer associated with (1) mismatch repair-deficient (dMMR) or (2) mismatch repair-proficient (pMMR), as determined by immunohistochemistry (IHC), that progressed during or after a platinum-based chemotherapy regimen. Patients received 500 mg dostarlimab intravenously every 3 weeks for 4 cycles, then 1000 mg every 6 weeks until disease progression, discontinuation, or withdrawal. The primary end points were the objective response rate (ORR) and duration of response (DOR), by blinded independent central review using RECIST v1.1.

Results: In total, 126 patients with dMMR and 145 with pMMR endometrial cancer identified by IHC were enrolled in the study and received dostarlimab. Of these, 103 and 142 patients, respectively, had sufficient follow-up time (24 weeks) for efficacy analyses. The mean follow-up was 16.3 months for patients with dMMR disease and 11.5 months for patients with pMMR disease. The ORR was 44.7% for patients with dMMR and 13.4% for patients with pMMR disease, with complete response seen in 10.7% and 2.1% of patients, respectively. Partial response was recorded in 34.0% of patients with dMMR disease and 11.3% of patients with pMMR disease; stable disease was recorded in 12.6% and 21.8% of patients, respectively. The disease control rate was 57.3% and 35.2%, respectively. Ongoing response was identified in 89.1% of patients with dMMR disease and 63.2% of patients with pMMR. The median DOR and overall survival were not reached. The 18-month DOR was 79.2% and 61.3%, respectively. The most common grade ≥3 treatment-emergent adverse events (AEs; N = 271) were anemia (12.2%), abdominal pain (4.8%), and dyspnea (4.1%). The most common grade ≥3 immune-related AEs were diarrhea, aspartate aminotransferase increased, and alanine aminotransferase increased (1.8% each). No treatment-related deaths occurred.

Conclusion: Dostarlimab demonstrated durable antitumor activity in patients with advanced or recurrent dMMR or pMMR endometrial cancer. dMMR status by IHC was associated with a higher response rate. No new safety signals were detected. These cohorts represent the largest prospective evaluation of a PD-1 (or PD-L1) therapy in endometrial cancer to date.

  1. Oaknin A, Tinker AV, Gilbert L, et al. Clinical activity and safety of the anti-programmed death 1 monoclonal antibody dostarlimab for patients with recurrent or advanced mismatch repair-deficient endometrial cancer: a nonrandomized phase 1 clinical trial. JAMA Oncol. 2020;6:1-7.
Related Items
Clinical Pharmacist–Initiated Tyrosine Kinase Inhibitor Discontinuation in Patients with Chronic Myeloid Leukemia
JHOP - March 2023 Vol 13 Special Feature published on March 23, 2023 in HOPA Abstracts
Evaluation of Chemotherapy-Induced Myelosuppression in Patients with Extensive-Stage Small-Cell Lung Cancer Who Received Trilaciclib: Retrospective Analysis of Florida Community Oncology Practices
JHOP - March 2023 Vol 13 Special Feature published on March 23, 2023 in HOPA Abstracts
Evaluation of the Safety of the New Alcohol-Containing Formulation of Cyclophosphamide
JHOP - March 2023 Vol 13 Special Feature published on March 23, 2023 in HOPA Abstracts
Health System Specialty Pharmacy Integration Impact on Prescription Fill Time
JHOP - March 2023 Vol 13 Special Feature published on March 23, 2023 in HOPA Abstracts
Invasive Fungal Disease in Patients with Hematologic Malignancies Receiving Micafungin Prophylaxis
JHOP - March 2023 Vol 13 Special Feature published on March 23, 2023 in HOPA Abstracts
Knowledge Gaps and Educational Needs for Common Cancer Therapy–Related Cardiovascular Adverse Events and Related Drug Interactions
JHOP - March 2023 Vol 13 Special Feature published on March 23, 2023 in HOPA Abstracts
Multidisciplinary Approach in Maximizing Oncology Clinic Throughput in a Comprehensive Cancer Center
JHOP - March 2023 Vol 13 Special Feature published on March 23, 2023 in HOPA Abstracts
Optimization of Rasburicase Dose for the Management of Tumor Lysis Syndrome in Community Oncology Practices
JHOP - March 2023 Vol 13 Special Feature published on March 23, 2023 in HOPA Abstracts
Pharmacist-Led 14-Day Oncolytic Drug Check-In Protocol
JHOP - March 2023 Vol 13 Special Feature published on March 23, 2023 in HOPA Abstracts
Safety of Rapid Dose Escalation of Venetoclax in Patients with Hematologic Malignancies
JHOP - March 2023 Vol 13 Special Feature published on March 23, 2023 in HOPA Abstracts
© Amplity Health. All rights reserved.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: